10.1523/JNEUROSCI.5018-12.2013 J
Site-specific absorption: While studies suggest minimal differences, anecdotal reports hint that stomach injections may deliver higher drug concentrations, with stronger side effects to match
The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
The choice of diluent depends on the intended laboratory application
11-15 Treatment of obstructive sleep apnoea Weight management Weight management continues to be a priority in the current OSA management guidelines, aiming to reduce disease severity and improve long-term health outcomes
Vad sger Jonatan Lamy, ordfrande fr Sveriges elevkrer om detta
